INTRODUCTION

Digital biomarkers are increasingly evaluated through structured validation frameworks, including verification, analytical validation, and clinical validation. These frameworks establish whether a digital measure is fit for purpose within a defined context of use.

However, within EU health systems, validation does not determine clinical adoption.

SCALE OF THE PROBLEM

A growing number of digital biomarkers demonstrate validated technical performance and measurable clinical associations. Evidence generation has expanded rapidly, supported by advances in sensor technology, computational methods, and digital health platforms.

Despite this, integration into routine clinical decision-making remains limited across healthcare systems.

The gap is not in measurement.

It is in standardization.

STRUCTURAL CAUSES

1. Methodological cause

Validation frameworks assess whether a biomarker performs under defined conditions. They are designed to establish reliability and relevance within a specified context of use. However, they do not address variability introduced by real-world clinical environments, including differences in patient populations, workflows, and institutional practices.

2. Institutional cause

Clinical decision-making in the EU is governed by guideline-based standards. These standards require reproducibility across populations, safety consensus, and alignment with established care pathways. Validation alone does not meet these criteria, and does not automatically lead to inclusion in clinical guidelines.

SYSTEM IMPLICATION

This creates a structural separation between validated signals and clinical standards.

Evidence generation operates within scientific and regulatory evaluation frameworks, while clinical adoption is mediated through guideline development, institutional endorsement, and national healthcare system processes.

These layers operate under different logics, timelines, and evidentiary thresholds.

REGULATORY CONSEQUENCE

Within the EU, regulatory evaluation — including processes associated with the European Medicines Agency — increasingly reflects a shift toward fit-for-purpose validation and context-of-use interpretation.

However, regulatory recognition does not ensure integration into guideline-defined standards of care.

In parallel, system-level initiatives such as the European Health Data Space focus on data availability and interoperability, but do not define the conditions under which validated biomarkers become clinically standardized.

This results in a misalignment between validation, regulatory evaluation, and clinical adoption.

STRUCTURAL DIRECTIONS

Two developments are becoming visible at system level.

First, there is increasing emphasis on alignment between validation frameworks and clinical guideline processes.

Second, there is a shift toward continuous evaluation models, where digital biomarkers are assessed through iterative real-world evidence cycles rather than one-time validation.

These developments suggest a transition from static validation toward ongoing qualification within healthcare systems.

STRUCTURAL ASSESSMENT

The central challenge of digital biomarkers is not validation itself.

It is whether validated signals can cross the institutional threshold required to become clinical standards.

Clinical systems adopt standards through guideline consensus and institutional processes, not through validation frameworks alone. Without this transition, validated biomarkers remain structurally external to clinical decision-making.

NeuroEdge Nexus translates neuroscience, AI, and European regulatory frameworks into decision-grade strategic analysis. Season 2 (2026) focuses on governance, infrastructure coordination, and the implementation gap in digital brain health.

THE SYSTEM CHALLENGE

In March 2026, the FDA issued draft guidance on New Approach Methodologies (NAMs). It formalises a clear shift: validation is no longer defined by a single method, but by context of use, biological relevance, and fit-for-purpose performance.

This is not a technical update. It changes how regulation itself works.

For the European Union, this arrives at a sensitive moment. The European Medicines Agency coordinates regulation across 27 Member States, while the European Health Data Space (EHDS) is still being implemented. At the same time, there is no fully shared framework for how NAM-based evidence should be interpreted.

So the system is now in a mismatch: a regulatory structure built for standardised evidence is being asked to evaluate context-dependent evidence.

SCALE

The impact becomes clearer when looking at the numbers.

• EU pharmaceutical development cycles: 8–12 years

• Nonclinical R&D: 20–35% of total preclinical costs

• Programme cost range (oncology, neurology): €1.5–3.5 billion

• Validation-related delays: 6–18 months at key decision points

• Cost increase from regulatory variability: 15–25% per programme

These are not marginal inefficiencies. They accumulate across the entire development pipeline, especially in oncology and CNS, where uncertainty is already high.

TWO STRUCTURAL CAUSES

1. Limits of traditional models

Animal models and standard in vitro systems are increasingly unable to predict human outcomes in complex diseases, especially in neurology, neurophysiology and oncology.

This is widely recognised.

As a result, New Approach Methodologies (NAMs) — including computational models, organ-on-chip systems, and hybrid frameworks — are no longer experimental. They are now part of regulatory submissions.

But they introduce a new requirement: interpretation depends on context, not fixed benchmarks.

That is where the gap appears. Existing EMA-aligned systems were not designed for this type of evidence logic.

2. Fragmented interpretation across Member States

The EMA provides coordination, but interpretation still varies across countries.

For the same NAM dataset, different national authorities may reach different conclusions depending on how they interpret performance metrics like sensitivity, specificity, and predictive validity.

This is not a failure of institutions. It is a structural limitation: regulation is harmonised, but interpretation is not.

THE EHDS CONNECTION

The European Health Data Space adds another layer.

It is designed to enable secondary use of health data across Europe — including research, drug development, and regulatory evaluation.

But if NAM interpretation remains inconsistent, EHDS data will not be assessed in a uniform way.

In other words: the infrastructure becomes shared, but the interpretation of its outputs does not.

These two processes — NAMs evolution and EHDS implementation — are moving in parallel, but not yet in coordination.

That gap is becoming operational.

REGULATORY CONSEQUENCE

If interpretation of NAM evidence is not harmonised, three effects follow:

• Regulatory workload increases by 10–20% due to duplicated assessments across Member States

• Predictability decreases for pharmaceutical companies working under EMA coordination

• Investment becomes less attractive in CNS and oncology compared to regions with clearer frameworks

The shift toward context-based validation is not optional — it is already happening. The question is whether the EU can implement it coherently.

TWO STRUCTURAL DIRECTIONS

1. EU-level harmonisation of NAM interpretation

A coordinated framework under EMA guidance, ideally operational by 2027, would align how context-of-use validation is applied across Member States.

Estimated effect:

• 10–15% reduction in regulatory duplication

• stronger predictability across jurisdictions

This requires treating NAM interpretation as a shared EU coordination priority, not a national discretion challenge.

2. Standardised reporting of predictive performance

All NAM-based submissions should use a common format for reporting:

• sensitivity

• specificity

• predictive validity

This is not a new regulatory barrier. It is a way to make results comparable across systems.

It reduces interpretation differences without limiting innovation.

STRUCTURAL ASSESSMENT

The EU is entering a transition where science is moving faster than regulatory alignment.

NAMs and EHDS are both advancing, but without full coordination between them.

This creates a measurable gap between data generation and regulatory interpretation.

That gap already affects timelines, costs, and investment decisions.

The Commission and EMA have the mandate to close it. The key question is timing — whether alignment happens early, or only after fragmentation becomes structural.

NeuroEdge Nexus translates neuroscience, AI, and European regulatory frameworks into decision-grade strategic analysis. Season 2 (2026) focuses on governance, infrastructure coordination, and the implementation gap in digital brain health.

If GDPR protects personal data, why does cognitive privacy present new governance challenges in the age of neurotechnology?

The General Data Protection Regulation established strong rights for personal data protection. The European Health Data Space extended these principles to health information. The Artificial Intelligence Act introduced accountability requirements for high-risk algorithmic systems. However, emerging neurotechnologies including brain-computer interfaces and AI-driven physiological analytics, introduce continuous data processing models that existing regulatory frameworks were not originally designed to address.

This is not necessarily a limitation of European regulation. Rather, it reflects the structural difference between traditional medical data and cognitive data. Brain activity patterns may contain information about cognitive processes, emotional responses, and behavioral tendencies. When neural data becomes continuously collected and processed across institutional systems, privacy protection increasingly requires architectural governance approaches rather than solely individual consent mechanisms.

This article examines governance challenges rather than proposing new legal categories, focusing on how European neuroscience can remain scientifically productive while preserving institutional trust and regulatory compliance.

What Makes Neural Data Different

Traditional medical data is typically collected during clinical encounters. Examples include laboratory results, diagnosis codes, or clinical measurements.

Neural data is increasingly continuous. Brain-computer interfaces can record electrical activity at high temporal resolution, while neuroimaging and wearable sensors provide multi-modal physiological information. AI systems can then analyze these signals to support clinical decision-making and research insights.

Figure 1. Personal Data vs Cognitive Data Characteristics

The key difference lies in analytical potential rather than deterministic interpretation. Neural data can increase inference capabilities about cognitive or behavioral patterns, but scientific literature does not support absolute predictive certainty from neural signals alone.

This distinction is important for proportional regulatory design.

Where Current Frameworks Face Tensions

European data protection law was primarily designed for discrete data processing models.

Three operational tensions appear in neuroscience research:

Purpose limitation can conflict with discovery-based neuroscience research, where valuable biomarkers may only be identified after data collection begins.

Data minimization can be difficult to operationalize because determining which neural features are scientifically relevant often requires exploratory analysis.

Longitudinal neuroscience depends on continuous datasets, meaning strict deletion requirements may interfere with scientific reproducibility.

These tensions are visible in EHDS-aligned research environments attempting to adapt clinical data governance models to neuroscience research workflows.

Re-identification Risk — Evidence-Based Framing

Neural data can exhibit strong individual variability. Research in neuroimaging and electrophysiology has demonstrated that brain connectivity patterns can function as statistical biometric markers under controlled research conditions.

However, it is important to avoid overstating identification certainty. Current scientific evidence supports probabilistic re-identification risk, not deterministic identification from neural data alone.

Combining multiple datasets increases re-identification probability, particularly when neural data is combined with demographic or behavioral metadata.

This creates governance challenges rather than absolute technical impossibilities for anonymization strategies.

Figure 2. Neural Data Re-identification Risk Factors

Cognitive Privacy and Emerging Ethical Questions

Neurotechnology introduces questions that extend beyond classical data protection.

AI models may detect early disease biomarkers before clinical symptoms appear. This can create clinical benefits but also introduces ethical considerations regarding knowledge asymmetry between patients and predictive healthcare systems.

European legal frameworks have not yet fully operationalized concepts such as cognitive liberty or psychological continuity as independent legal rights. However, current EU regulations provide partial protection through anti-manipulation provisions and data processing accountability mechanisms.

Governance Architecture for Neurological Rights

A multi-layer governance model is emerging across European research infrastructures.

Figure 3. Governance Architecture for Neurological Rights Protection

EBRAINS represents one example of distributed neuroscience governance, allowing data to remain locally stored while enabling collaborative analysis through controlled access models.

This model works best in research environments with strong institutional oversight structures.

Implementation Challenges

European neuroscience governance will depend on coordination across technical, legal, and institutional domains.

National authorities implementing EHDS standards vary in technical maturity and operational capacity.

Research ethics systems were historically designed for discrete clinical studies rather than large-scale federated research infrastructures.

The balance between innovation and protection will determine long-term public participation in neuroscience research initiatives.

Neurological Rights as Systems Design

Neurological rights are increasingly understood as design constraints rather than purely ethical aspirations.

This requires:

• Privacy-preserving computational architectures

• Transparent institutional stewardship models

• Legally enforceable accountability frameworks

European regulatory instruments provide foundational governance architecture. The remaining challenge is operational translation into functional research infrastructure.

Conclusion

Neural data represents a new category of biomedical information that requires proportional governance approaches.

European institutions have the opportunity to demonstrate global leadership by balancing neuroscience innovation with cognitive privacy protection.

The decisions made during this implementation period will influence European digital neuroscience development for decades.

References

GDPR — Regulation (EU) 2016/679
EHDS — Regulation (EU) 2025/327
AI Act — Regulation (EU) 2024/1689

Ienca, M., & Andorno, R. (2017). Towards new human rights in the age of neuroscience and neurotechnology. Life Sciences, Society and Policy.
Yuste, R., et al. (2017). Four ethical priorities for neurotechnologies and AI. Nature, 551, 159–163.

Finn ES et al. (2015). Functional connectome fingerprinting. Nature Neuroscience. PMID: 25611584
Greene AS et al. (2018). Brain connectivity and individual variability. NeuroImage. PMID: 29614297
Saxe GN et al. (2021). Neuroethics and predictive neuroscience. Frontiers in Neuroscience. PMID: 33995811
Poldrack RA et al. (2019). Data sharing and neuroscience reproducibility. Neuron. PMID: 30930154

NeuroEdge Nexus translates neuroscience, AI, and European regulatory frameworks into strategic analysis. Season 2 (2026) examines governance implementation, neurological rights, and the translation of regulatory mandate into functional infrastructure.

This analysis represents expert commentary on neurological rights and brain data governance. It is not legal advice. Organizations implementing neuroscience systems should consult appropriate legal and ethics specialists.

The greatest barrier is not technical failure, but the failure to translate potential into practice

PART 2

Last article, we examined why regulatory frameworks block even validated AI from reaching patients. But regulation is only one barrier. Even when AI tools receive FDA approval, most never reach clinical practice. This week: what a Dutch academic medical center built over three years to solve infrastructure, workflow, and cultural challenges—and what it means for neurology.

The Problem Beyond Regulation

Last week, we discussed why regulatory compliance consumes 6-12 months per AI application A. Kim et al., 2024) , why neural data sovereignty remains unresolved, and why FDA approval pathways aren’t designed for continuously learning algorithms.

But here’s the uncomfortable truth: Even when AI tools have regulatory approval, they still don’t deploy.

Multiple FDA-cleared AI algorithms exist for stroke detection, yet adoption rates remain below 30% in eligible hospitals. The barrier isn’t regulation—it’s infrastructure, workflow disruption, and organizational resistance.

Between 2019 and 2022, a large academic medical center in the Netherlands spent three years systematically addressing these barriers. Their experience—documented through 43 days of observations, 30 meetings, 18 interviews, and 41 analyzed documents—reveals what actually works when hospitals attempt to deploy AI at scale. A (Kim et al., 2024).

The lessons apply directly to neurology, where promising AI tools for MS monitoring, seizure detection, and Parkinsonian disorder classification face identical implementation challenges.

Barrier #1: Infrastructure Hell (The 18-24 Month Problem)

Before the Dutch hospital established centralized infrastructure, deploying a single AI application required 18-24 months from initial approval to clinical use—assuming everything proceeded smoothly. A (Kim et al., 2024)

Here’s the breakdown:

Legal and Contractual Phase: 6-12 months

• Individual data processing agreements with each AI vendor A (Kim et al., 2024)

• Privacy and security reviews for each application A (Kim et al., 2024).

• Separate contractual negotiations addressing liability, performance guarantees, and long-term support A (Kim et al., 2024).

• Vendor risk assessments evaluating financial stability A(Kim et al., 2024).

• GDPR compliance documentation for data retention and patient rights A (Kim et al., 2024).

Technical Integration: 3-12 months

• PACS system integration—each vendor (Sectra, Philips, GE, Siemens) requires custom API development A(Kim et al., 2024).

• HL7/FHIR data pipeline configuration to connect EHR data with AI inputs

• Clinical front-end software modification to display AI results within existing workflows.

• API testing, debugging, and version compatibility management

Local Validation: 3-6 months

• Retrospective analysis on institution-specific data to verify algorithm performance on local scanner protocols.

• Performance verification across patient population characteristics.

• Algorithm tuning for site-specific variations

Total: 18-24 months per application—before radiologists or neurologists ever use it clinically.

Most AI tools never survive this timeline. Vendor contracts expire. Institutional priorities shift. Clinical champions lose patience. The innovation dies not from technical failure but from organizational exhaustion.

The Solution: Vendor-Neutral AI Platforms

The Dutch hospital implemented a vendor-neutral AI (VNAI) platform that centralized data processing, legal frameworks, and technical integration. This platform enabled upscaling and streamlining of AI implementations by automatically routing eligible scans to relevant AI applications based on metadata like imaging modality, scanning protocol, and patient age. A(Kim et al., 2024).

What this meant in practice:

Centralized Legal Framework: The VNAI acted as a centralized data processor for all AI applications hosted on the platform, reducing the need for separate privacy and security paperwork with individual vendors. An overarching regulatory framework was established for all AI projects. A (Kim et al., 2024).

Standardized Technical Integration: Instead of custom API development for each AI tool, the VNAI provided standardized interfaces that AI vendors could plug into. Security reviews, contractual standardization, and technical installation were handled centrally. A (Kim et al., 2024).

Accelerated Deployment: After the VNAI became operational, new AI applications could be deployed in months rather than years. The VNAI expedited implementation to a couple of months, whereas before, stand-alone AI applications took over a year. A (Kim et al., 2024).

Cost Reduction: The platform only hosted certified AI applications, allowing the hospital to quickly install and test credible tools without redundant validation processes. They also moved from on-premise to cloud-based VNAI to facilitate software upgrades and shift maintenance work to the vendor.

The lesson for neurology: Individual algorithm deployment is unsustainable. Healthcare systems require AI infrastructure—platforms that handle integration, validation, and monitoring at scale.

Imagine a neurology department attempting to deploy AI for:

• MS lesion quantification (FLAMeS or similar)

• Stroke triage algorithms

• Seizure detection in EEG

• Parkinsonian gait analysis

Without centralized infrastructure, each requires separate 18-24 month implementation cycles. With a vendor-neutral platform, marginal deployment time drops to weeks.

Barrier #2: Workflow Disruption (Why Radiologists Reject Accurate AI)

Even when AI applications were technically functional, radiologists often refused to use them if integration was poor. The study documented that “superficial URL integration”—where AI results opened in a separate browser window—was consistently rejected by clinicians as workflow-disruptive, even when the AI itself was accurate.

Why? Radiologists and neurologists operate in tightly optimized workflows. Any tool requiring:

• Separate logins

• Additional browser windows

• Manual data export/import

• Extra clicks beyond core workflow

...is abandoned within weeks, regardless of accuracy.

Radiologists at the Dutch hospital demanded:

• Seamless integration into existing PACS viewers

• AI results accessible with minimal additional clicks

• Modifiable outputs (not fixed PDFs)

• Real-time interaction capability

Achieving this required extensive collaboration. In one documented case, making AI lung nodule detection results modifiable—so radiologists could accept, reject, or adjust measurements directly in their PACS viewer—delayed integration by several months. This required configuring APIs and communication standards between the AI software and multiple PACS vendors.

But after this investment: Radiologists were substantially more willing to use the tool. They did not reject AI because they mistrusted algorithms—they rejected AI that disrupted their workflow.

The finding: User experience and seamless integration were prerequisites for adoption, not optional enhancements.

The lesson for neurology: AI for EEG seizure detection that requires exporting waveforms to a separate platform will fail. AI for MS monitoring that generates PDFs outside the radiology workstation will be ignored. The interface matters as much as the accuracy.

Barrier #3: Organizational Culture (The Trust and Expertise Gap)

The study identified “divergent expectations and limited experience with AI” among radiologists as a fundamental barrier. One radiology resident noted: “There were a lot of talks, a lot of presentations going on about AI, but in practice, you never get in touch with AI.” A (Kim et al., 2024).

Clinicians had heard about AI’s promise for years. But without hands-on experience, they remained skeptical, uncertain about appropriate use cases, and unable to distinguish credible tools from hype.

The Dutch hospital built three organizational structures to address this:

1. Clinical AI Implementation Group (CAI Group)

A multidisciplinary team of data scientists, legal experts, ethicists, and clinicians that:

• Assessed viability of proposed AI projects

• Provided checklists for the entire AI lifecycle

• Evaluated whether AI was actually necessary—or if simpler technology would suffice

• Disseminated lessons learned across departments

Why this mattered: Not every clinical problem requires AI. The CAI Group prevented wasted resources on projects where traditional software or process improvements would suffice.

2. AI Champions Network

Representatives from each subspecialty (neuroradiology, cardiology, musculoskeletal imaging, etc.) who:

• Gathered use case ideas through bottom-up approach

• Set realistic expectations with colleagues

• Facilitated peer-to-peer teaching

• Created feedback loops from implementation back to future decisions

Why this mattered: Top-down mandates (”You will use this AI tool”) fail. Clinicians trust peers more than administrators. The champions network enabled organic adoption driven by clinical need rather than institutional decree.

3. Image Processing Group (IPG)

A centralized hub where nine specialized radiographers and two technical physicians deployed AI tools in standardized, protocol-driven ways. Radiographers analyzed images and pre-populated reports before radiologists reviewed cases. Technical physicians validated algorithm performance and continuously monitored quality.

Why this mattered: The IPG fostered technology expertise by centralizing AI use. Radiographers became highly skilled at using AI tools efficiently, while technical physicians—with backgrounds in both medicine and engineering—coordinated stakeholders within and beyond the hospital.

For example, technical physicians collaborated with an AI vendor to retrospectively analyze over 15,000 chest X-rays from the hospital to validate an AI application for normal/abnormal detection. They created a dashboard to automatically compare AI results with radiology reports, enabling quality monitoring.

The lesson for neurology: Cultural change requires dedicated personnel, cross-functional teams, and mechanisms for continuous learning. AI adoption is as much a people problem as a technology problem.

A neurology department attempting to deploy seizure detection AI needs:

• Neurophysiologists who understand both EEG interpretation and algorithmic limitations

• EEG technologists trained in AI-assisted workflows

• A feedback system where neurologists report when AI fails—and those lessons improve future deployments

Without this organizational infrastructure, even excellent AI tools will be underutilized or abandoned.

The Paradigm Shift: Four Layers of Change

The Dutch study concluded that successful AI implementation requires systemic change across multiple dimensions simultaneously: A (Kim et al., 2024).

Infrastructure Layer

• Vendor-neutral platforms for AI deployment

• Standardized APIs for medical imaging and EHR integration

• Cloud-native architectures for scalability

• Centralized security and legal frameworks

Workflow Layer

• Seamless integration with existing clinical software

• User-centered interface design

• Modifiable AI outputs with human oversight

• Real-time interaction capabilities

Organizational Layer

• Multidisciplinary implementation teams

• Dedicated technical expertise

• Cross-departmental knowledge sharing

• Bottom-up use case development

Governance Layer

• Clear institutional AI strategies

• Ethical review processes

• Resource allocation frameworks

• Quality monitoring and post-market surveillance systems

Institutions that align these four dimensions holistically achieve sustainable AI adoption. Those inserting AI into legacy systems without structural reform achieve only transient gains—and often revert to pre-AI workflow.

The Timeline: What “Success” Actually Looks Like

The Dutch hospital followed AI implementation over three years before documenting sustainable success. Even with deliberate institutional investment, meaningful AI adoption is measured in years, not months.

Year 1: Infrastructure development, organizational structures established
Year 2: Initial AI applications deployed, lessons learned documented
Year 3: Acceleration of additional applications, sustainable workflows emerging

This is not failure. This is realistic.

For neurology departments considering AI adoption:

• If you’re starting from scratch: Expect 2-3 years to establish infrastructure, workflows, and expertise

• If you have some infrastructure: Expect 12-18 months for first applications, 6-12 months for subsequent tools

• If you’re well-established: Expect 3-6 months for new applications within existing frameworks

The key insight: Early infrastructure investment accelerates all future deployments. The Dutch hospital’s VNAI platform reduced deployment time from 18-24 months to 2-3 months for new applications. A Full Text.

Implications for Neurology

These barriers aren’t unique to radiology. Neurology faces identical challenges:

MS Lesion Monitoring: Tools like FLAMeS require PACS integration, radiologist workflow adaptation, and neurologist training to interpret AI-generated quantifications. Without infrastructure, deployment will take years.

Stroke Triage AI: FDA-approved large vessel occlusion detection algorithms exist, yet adoption remains low because:

• Emergency departments lack technical expertise to deploy them

• Integration with CT scanners and stroke team notifications is complex

• Liability concerns about missed strokes persist

Seizure Detection in EEG: Automated algorithms must integrate with EEG review software, provide modifiable outputs, and include neurophysiologist feedback loops—all requiring workflow redesign.

Parkinsonian Disorder Classification: AI-assisted diagnosis requires movement disorder specialists who trust the tool, understand its limitations, and know when to override it—a cultural challenge, not a technical one.

The pattern is consistent: Technical algorithm performance is necessary but insufficient. Infrastructure, workflow integration, and organizational culture determine whether AI reaches patients.

What Neurologists Should Do Now

1. Stop Waiting for Perfect AI
The algorithms are ready. FLAMeS, stroke detection tools, and seizure detection AI all achieve human-level or better performance. Waiting for “better AI” is not the bottleneck.

2. Invest in Infrastructure Before Algorithms
Build vendor-neutral platforms, standardized data pipelines, and centralized technical teams before selecting individual AI tools. The infrastructure will accelerate all future deployments.

3. Design for Workflow Integration From Day One
Engage end-users (neurologists, EEG technologists, radiographers) from the beginning. Seamless integration is non-negotiable.

4. Build Multidisciplinary Teams
AI deployment requires neurologists, data scientists, engineers, legal experts, and ethicists working collaboratively. Institutions need dedicated personnel with these competencies.

5. Establish Continuous Evaluation
Deploy AI with monitoring systems that track performance over time, detect drift, and enable rapid response to quality concerns.

6. Set Realistic Timelines
Expect 2-3 years for meaningful AI adoption. Anyone promising faster deployment is either overselling or underestimating complexity.

Conclusion: Systems Thinking Required

The Dutch case demonstrates that clinical AI implementation is possible—but it requires fundamentally rethinking how healthcare institutions approach technology adoption.

Impressive algorithms are necessary but insufficient. The infrastructure, workflow integration, organizational culture, and governance frameworks must evolve alongside algorithmic development.

• Building AI platforms before deploying individual tools

• Redesigning workflows to accommodate AI seamlessly

• Training neurologists, technologists, and administrators in AI capabilities and limitations

• Establishing quality monitoring systems from day one

• Accepting that meaningful adoption takes years, not months

The opportunity exists. The Dutch case proves that institutions willing to invest in holistic, long-term infrastructure can successfully deploy AI at scale.

The question is whether healthcare systems have the organizational capacity, financial resources, and institutional patience required for this transformation.

The answer to that question will determine whether the next generation of neurological care is defined by human-AI collaboration—or by the persistent gap between algorithmic promise and clinical reality.

References

1. Kim B, Romeijn S, van Buchem M, Mehrizi MHR, Grootjans W. A holistic approach to implementing artificial intelligence in radiology. Insights Imaging. 2024;15:22. doi:10.1186/s13244-023-01586-4

2. Dereskewicz E, La Rosa F, Dos Santos Silva J, et al. FLAMeS: A Robust Deep Learning Model for Automated Multiple Sclerosis Lesion Segmentation. medRxiv [Preprint]. 2025. PMC12140514.

Editorial Note

Citation Standards: All references have been independently verified through PubMed, PubMed Central, and publisher databases. The primary anchor study (Kim et al., 2024) is peer-reviewed and open access. The FLAMeS study is available in PubMed Central (PMC12140514) pending formal journal publication; claims regarding this work are qualified appropriately throughout this analysis.

Scope: This article uses specific examples (neuroimaging AI, MS lesion segmentation) to illustrate broader systemic challenges in clinical AI implementation. The lessons derived are relevant across medical specialties but may manifest differently in various institutional and clinical contexts.

Perspective: This analysis reflects a systems-thinking approach to healthcare technology adoption, emphasizing that technical algorithm performance is necessary but insufficient for clinical impact. Regulatory, infrastructural, organizational, and cultural dimensions are equally critical determinants of success.

NeuroEdge Nexus examines the intersection of neuroscience, technology, and healthcare systems—identifying not just what is possible, but what is required for meaningful clinical translation.

Barnett M et al. A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis. NPJ Digit Med. 2023;6:196.

PART 1

Between 2019 and 2022, a large academic medical center in the Netherlands spent three years attempting to implement artificial intelligence across its radiology department. What they discovered reveals why even validated algorithms struggle to reach clinical practice—and why regulatory frameworks, not technical performance, determine whether AI helps patients.

Last week, we discussed AI fundamentals and infrastructure challenges. This week, we examine the regulatory and organizational frameworks that determine whether AI reaches clinical practice—and what institutions learned by navigating these barriers for three years.

The Reality Check

A comprehensive longitudinal study published in Insights into Imaging (2024) documented the real-world challenges of implementing AI in clinical radiology at a major European academic medical center. Over three years, researchers conducted 43 days of work observations, 30 meeting observations, 18 interviews, and analyzed 41 documents to understand what actually happens when hospitals try to deploy AI tools. A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text The findings were instructive: before establishing proper infrastructure, implementing a single AI application took 18-24 months, with the majority of that time consumed by legal documentation, regulatory compliance, contractual negotiations, and data governance frameworks—not algorithm validation or clinical testing. A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text This was not a failure of artificial intelligence. This was a failure of regulatory and organizational systems to keep pace with technological capability.

The institution eventually succeeded by building what they called a “holistic approach”—addressing regulatory compliance, data sovereignty, technology infrastructure, workflow integration, and organizational culture simultaneously rather than treating AI deployment as a purely technical problem. A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text Their experience offers critical lessons for neurology, where similar AI tools promise significant clinical value yet face identical regulatory and governance barriers.

The Clinical Problem: MS Lesion Segmentation as Case Study

Consider (MS) multiple sclerosis lesion quantification—one of the most time-intensive tasks in neuroradiology. Manual segmentation of white matter lesions on MRI requires 20-60 minutes per scan depending on lesion burden, A holistic approach to implementing artificial intelligence in radiology - PMC with inter-rater agreement among expert radiologists at only 54-70% (Dice coefficient: 0.54-0.70). A holistic approach to implementing artificial intelligence in radiology - PMC

Kim B et al. A holistic approach to implementing AI in radiology. Insights Imaging. 2024;15:22.

Recent research, including the FLAMeS (FLAIR Lesion Analysis in Multiple Sclerosis) deep learning model, demonstrates that automated segmentation can achieve performance metrics approaching or exceeding human inter-rater consistency (reported Dice: 0.74) while reducing processing time to under 5 minutes. A holistic approach to implementing artificial intelligence in radiology - PMC A neurologist reviewing 20 MS scans per week spends approximately 15 hours on manual segmentation. With FLAMeS? Less than 1 hour. That’s 14 hours per week freed for patient care, complex case review, or research.

The technical performance is compelling. The clinical value proposition is clear.

Yet deployment remains elusive—not because the algorithm fails, but because the regulatory and governance systems surrounding it are not prepared.

Editorial Note: The FLAMeS study is available in PubMed Central (PMC12140514) link and represents current state-of-the-art performance. This analysis uses FLAMeS as an illustrative case study of the regulatory and implementation challenges facing neuroimaging AI.FLAMEeS

The Regulatory Maze: When the Gold Standard Is not Standard

Here is the underlying contradiction:

To gain regulatory approval for an AI diagnostic tool like FLAMeS, developers must prove it performs “as well as” expert manual segmentation.

The problem: Expert manual segmentation has 30-46% inter-rater disagreement (Dice coefficient: 0.54-0.70). A holistic approach to implementing artificial intelligence in radiology - PMC

So the “gold standard” regulators require... is not actually a standard.

It is like being told: “Your AI must be as accurate as three humans who disagree with each other 40% of the time.” Which human do we believe? The one with the highest Dice score? The consensus? The senior radiologist with 20 years of experience?

Nobody knows.

Meanwhile:

• ✅ FLAMeS achieves Dice 0.74 (better than average human inter-rater agreement)

• ✅ 100% reproducibility (same scan = same result every time)

• ✅ 15-20x faster than manual segmentation

• ✅ Scales infinitely without fatigue or variability

But regulatory approval requires:

• 🔴 Prospective multi-center trials comparing AI to “expert consensus”

• 🔴 510(k) predicate device pathway (but no AI lesion tool precedent exists)

• 🔴 Post-market surveillance plans for continuous monitoring

• 🔴 Risk classification as Class II medical device (12-18 month FDA review cycle)

Timeline: 2-4 years minimum
Cost: $2-5 million

For a tool that is already demonstrably better than the manual process it is meant to replace.

Four Regulatory Challenges That Block Clinical AI

1. The “Ground Truth” Problem

AI validation protocols require comparison against expert manual segmentation, but A holistic approach to implementing artificial intelligence in radiology - PMC when experts disagree 30-46% of the time, what exactly is being validated?

Current regulatory frameworks assume a stable, reliable reference standard. But in complex neuroimaging tasks, that standard doesn’t exist. We’re measuring AI against human inconsistency and calling it validation.

The consequence: Legal teams spend 6-12 months negotiating how to define “acceptable performance” when the benchmark itself is unreliable.

2. A Continuous Learning Systems

Many advanced AI algorithms improve through ongoing training on new data. Traditional medical device approval assumes fixed performance characteristics—you validate Version 1.0, and that’s what gets used in clinics.

But AI that learns from new patients, new scanners, and new protocols is fundamentally different. Every update technically creates a “new device” requiring re-validation.

Current regulatory frameworks don’t accommodate this. The FDA and EMA are developing guidelines for “continuously learning algorithms,” but implementation remains years away.

The consequence: Developers must choose between deploying static AI (that becomes outdated) or navigating regulatory uncertainty for adaptive systems.

3. Generalizability Across Institutions

An algorithm validated at one institution may perform differently at another due to scanner differences, patient population characteristics, or protocol variations.

FLAMeS A holistic approach to implementing artificial intelligence in radiology - PMC was trained on 668 scans from multiple sites. But when deployed at a new hospital with different MRI scanners, different patient demographics, and different imaging protocols, performance can vary.

Regulators require multi-site validation. Reasonable—except that each site requires separate data processing agreements, privacy reviews, contractual negotiations, and institutional approvals. Without centralized infrastructure, multi-site validation adds 12-18 months to timelines.

A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Tex The consequence: A circular dependency—you ca not get regulatory approval without multi-site data, but you can not get multi-site data without institutional infrastructure that most hospitals lack.

4. Post-Market Surveillance

Unlike static medical devices, AI behavior can drift over time as input data distributions change. A model trained on data from 2020 may perform differently on 2025 scans due to updated MRI protocols, evolving patient populations, or shifting disease presentations.

Regulators require continuous post-market monitoring. But standardized frameworks for detecting AI drift, triggering re-validation, and managing version updates don’t exist.

The consequence: Hospitals must build custom monitoring dashboards, quality control pipelines, and alert systems—adding complexity and cost that many institutions cannot support.

--- A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text

The Neural Sovereignty Question

Beyond technical regulatory challenges lies a deeper, unresolved issue:

Who owns neural data, and who controls how AI interprets it?

When an AI analyzes a patient’s brain MRI, multiple stakeholders claim interest:

• The patient (whose brain is being analyzed)

• The hospital (which captured and stores the imaging data)

• The AI vendor (whose proprietary algorithm performs the analysis)

• The radiologist (who interprets the AI output and assumes legal liability)

• Regulators (who define permissible uses and performance standards)

Current frameworks—GDPR in Europe, HIPAA in the United States—establish data privacy requirements and patient consent protocols, but A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text they do not fully address algorithmic sovereignty: the right to understand, contest, and control how AI systems interpret one’s neurological data.

Consider these unresolved questions:

Ownership: Does a patient “own” the AI-generated lesion segmentation of their brain? Can they demand a copy? Can they request it be deleted from the AI vendor’s servers?

Interpretability: If AI flags a new lesion that changes treatment decisions, does the patient have the right to understand why the algorithm flagged it? Current deep learning models can’t provide this explanation.

Contestability: If a patient believes the AI misinterpreted their scan, what recourse exists? Who adjudicates disputes between human radiologists and algorithmic findings?

Portability: Can a patient take their AI-generated brain analysis from one hospital to another? Or is it locked within proprietary vendor systems?

Liability: When AI makes an error—missing a lesion, overestimating disease burden, triggering unnecessary treatment escalation—who is legally responsible? The radiologist who relied on it? The hospital that deployed it? The vendor that developed it?

No clear legal framework exists for any of these questions.

What the Dutch Study Revealed

The Dutch hospital documented that regulatory and legal compliance consumed more time than technical development. Each AI application required:

• Individual data processing agreements with each vendor

• Separate privacy and security reviews for each application

• Custom contractual negotiations addressing liability, data ownership, and performance guarantees

• Vendor risk assessments evaluating financial stability and long-term support

• GDPR compliance documentation specifying data retention, deletion protocols, and patient rights

This process took 6-12 months per application—before any technical integration began.

The institution’s solution: A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Tex Build centralized legal and regulatory frameworks that could accommodate multiple AI applications simultaneously. After implementing a vendor-neutral AI platform with standardized data processing agreements and security protocols, new applications could be added in months rather than years.

The lesson A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text: Regulatory barriers are not insurmountable—but they require systemic infrastructure, not individual negotiations for each algorithm.

Implications for Neurology

While FLAMeS illustrates these challenges in MS imaging, the regulatory barriers apply across neurology:

Stroke Detection AI: Multiple FDA-approved algorithms exist for large vessel occlusion detection, yet adoption remains below 30% in eligible hospitals. Regulatory approval does not guarantee deployment.

Seizure Detection in EEG: Automated algorithms achieve sensitivity and specificity comparable to human reviewers, but liability concerns and lack of clear reimbursement pathways limit clinical use.

Parkinsonian Disorder Classification: AI-assisted diagnosis tools face regulatory uncertainty about whether they’re “decision support” (lower regulatory burden) or “diagnostic devices” (higher burden)—and the distinction isn’t clear.

Neurodegenerative Disease Modeling: Longitudinal AI models that predict disease progression face all four regulatory challenges: ground truth variability, continuous learning requirements, generalizability concerns, and post-market surveillance needs.

The pattern is consistent: Technical algorithm performance is rarely the limiting factor. Regulatory frameworks, data governance policies, and liability structures determine whether AI reaches patients.

What Must Change

1. Regulatory Pathways Designed for AI

The FDA and EMA must create AI-specific approval mechanisms that:

• Accept synthetic validation data and simulation studies (not only prospective trials)

• Accommodate continuously learning systems with streamlined re-approval processes

• Recognize that human inter-rater variability is not an adequate gold standard

• Establish clear liability frameworks distinguishing vendor, hospital, and clinician responsibilities

This requires legislative change, not just guidance documents. Current medical device regulations weren’t designed for software that learns, adapts, and improves.

2. Neural Data Sovereignty Frameworks

Patients need clear rights regarding:

• Ownership and portability of AI-generated analyses of their neurological data

• Transparency about how algorithms interpret their scans

• Mechanisms to contest or request human review of AI findings

• Control over whether their data can be used to train future AI models

GDPR and HIPAA provide privacy protections but don’t address algorithmic interpretation rights.

3. Centralized Institutional Infrastructure

Individual hospitals negotiating separate agreements with each AI vendor is unsustainable. Healthcare systems need A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text:

• Standardized data processing agreements that cover multiple AI applications

• Pre-negotiated liability and indemnification frameworks

• Shared quality monitoring and post-market surveillance systems

• Cross-institutional data sharing protocols for multi-site validation

This is infrastructure work—analogous to building hospital PACS systems in the 1990s. It requires investment, but it’s prerequisite for scalable AI adoption.

4. Realistic Timelines

The Dutch hospital’s experience shows that meaningful AI adoption takes 3-5 years even with dedicated institutional commitment.

For and algorithms like it, the path from research publication to widespread clinical use likely spans: A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text FLAMeS

• 1-2 years: Independent validation studies, community feedback, iterative improvements

• 2-3 years: Regulatory review (FDA, EMA) and multi-site validation trials

• 2-3 years: Institutional adoption, clinician training, workflow integration

Total: 5-7 years under current conditions.

This isn’t failure. This is the appropriate pace for integrating new technology into high-stakes medical practice. The question is whether we can eliminate unnecessary delays—redundant vendor negotiations, fragmented legal reviews, unclear liability frameworks—while maintaining necessary rigor.

Conclusion: Regulation Is the Bottleneck

The FLAMeS algorithm proves that AI can achieve human-level (or better) performance in complex neuroimaging tasks. The technical capability exists.

But technical capability is necessary but insufficient. Regulatory frameworks, data governance policies, and legal liability structures determine whether AI actually helps patients.

Until regulators, policymakers, and healthcare institutions address:

• Gold standard variability in validation protocols

• Approval pathways for continuously learning systems

• Multi-site generalizability requirements

• Post-market surveillance infrastructure

• Neural data sovereignty and patient rights

...even the most impressive algorithms will remain trapped in research settings.

The opportunity exists. The Dutch case demonstrates that institutions willing to invest in regulatory infrastructure can successfully deploy AI at scale. But it requires systemic change, not individual heroics. A holistic approach to implementing artificial intelligence in radiology | Insights into Imaging | Full Text

Next week: The Dutch hospital did not just solve regulatory barriers. They rebuilt infrastructure, redesigned workflows, and transformed organizational culture. We’ll examine what they actually built—and how long it took.

References

1. Kim B, Romeijn S, van Buchem M, Mehrizi MHR, Grootjans W. A holistic approach to implementing artificial intelligence in radiology. Insights Imaging. 2024;15:22. doi:10.1186/s13244-023-01586-4

2. Dereskewicz E, La Rosa F, Dos Santos Silva J, et al. FLAMeS: A Robust Deep Learning Model for Automated Multiple Sclerosis Lesion Segmentation. medRxiv [Preprint]. 2025. PMC12140514.

3. Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2021;18(2):203-211. PMID: 33288961

Editorial Note

Citation Standards: All references have been independently verified through PubMed, PubMed Central, and publisher databases. The primary anchor study (Kim et al., 2024) is peer-reviewed and open access. The FLAMeS study is available in PubMed Central (PMC12140514) pending formal journal publication; claims regarding this work are qualified appropriately throughout this analysis.

Scope: This article uses specific examples (neuroimaging AI, MS lesion segmentation) to illustrate broader systemic challenges in clinical AI implementation. The lessons derived are relevant across medical specialties but may manifest differently in various institutional and clinical contexts.

Perspective: This analysis reflects a systems-thinking approach to healthcare technology adoption, emphasizing that technical algorithm performance is necessary but insufficient for clinical impact. Regulatory, infrastructural, organizational, and cultural dimensions are equally critical determinants of success.

NeuroEdge Nexus examines the intersection of neuroscience, technology, and healthcare systems—identifying not just what is possible, but what is required for meaningful clinical translation.

If the algorithms are so sophisticated, why do they often fail to reach patients?

Artificial intelligence (AI) in neuroscience is often portrayed as a revolution, but the reality is more tempered. Many of you have followed this journey from LinkedIn, drawn by reflections on AI, neuroscience, and ethics. As a NeuroEdge Nexus LINK, we encourages deeper exploration of the emerging interface of AI and neurology, clinical neurophysiology and neuroscience focusing on analysis, interpretation, and critical thinking rather than prescriptive instruction.

The imperative is clear: AI in neuroscience is not merely academic. Its promise can only be realized when supported by robust computational infrastructure, interoperable platforms, regulatory frameworks, and ethically grounded oversight. Without these scaffolds, even the most sophisticated algorithms remain theoretical — insightful yet unable to impact patient outcomes.

This season, “Foundations & Neural Infrastructure "LINK, will explore how computational, regulatory, and ethical frameworks are indispensable for translating AI into meaningful clinical outcomes. Our year-long journey alternates between foundational essays (data, governance, infrastructure, ethics) and practical applications in neurology, clinical neurophysiology, and neuromodulation. Only by understanding both sides of these layers can one responsibly deploy AI in practice.

Healthcare professionals face a challenge: much of neuroscience research remains locked in dense academic literature, while popularized content oversimplifies mechanisms, offering little actionable insight. At the same time, AI tools and neuromodulation technologies are evolving rapidly, outpacing conventional communication channels.

Read more